adverse events (TEAE) were diarrhea (29.2%), handefoot skin reaction (24.2%), fatigue (16.2%), and decreased appetite (14.3%). Incidence of TEAEs and drug-related TEAEs were comparable between patients with ChildePugh B liver function and the overall population.Conclusions: Sorafenib has been evaluated in broad patient populations in large, realworld, non-interventional studies, such as GIDEON and OPTIMIS. Despite differing timelines and study design, baseline characteristics were similar between patients enrolled in the GIDEON and OPTIMIS studies. Median OS for this extended patient population, including patient subgroups who were excluded from IMbrave150, was similar to the phase 3 SHARP study (10.7 months). 2 In addition, no new safety signals with sorafenib were identified. These data demonstrate the importance of patient characteristics to inform selection of first-line systemic therapy for HCC. 1.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.